New pill shows promise for untreated brain tumor patients
NCT ID NCT04458272
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a new drug called DS-1001b in 25 people with a specific type of slow-growing brain tumor (grade II glioma) that has an IDH1 mutation. Participants have not had chemotherapy or radiation before. The goal is to see if the drug can shrink or control the tumor and to check for side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for WHO GRADE II GLIOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Hiroshima University Hospital
Hiroshima, Japan
-
Kitasato University Hospital
Sagamihara, Kanagawa, Japan
-
Kumamoto University Hospital
Kumamoto, Japan
-
Kyorin University Hospital
Tokyo, Japan
-
Kyoto University Hospital
Kyoto, Japan
-
Nagoya University Hospital
Nagoya, Aichi-ken, Japan
-
National Cancer Center Hospital
Tokyo, Japan
-
National Hospital Organization Osaka National Hospital
Osaka, Japan
-
Saitama Medical University International Medical Center
Hidaka, Saitama, Japan
-
Tohoku University Hospital
Sendai, Miyagi, Japan
-
Tokyo Women's Medical University Hospital
Tokyo, Japan
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- New MRI technique could reveal hidden brain tumor activity
- New radiation method aims to protect scalp in brain tumor patients
- Custom video may ease brain tumor radiation anxiety
- New combo therapy targets aggressive brain tumors in phase 2 trial
- New hope for young brain tumor patients: drug combo targets IDH mutations